Ivermectin ineffective in preventing severe COVID-19-study [View all]

Related: Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities (JAMA Internal Medicine)

Earlier DU thread: Clinical Data just out - Ivermectin does not work on Covid

______________________________________________________________________

Source: Reuters

Ivermectin ineffective in preventing severe COVID-19-study

Fri, February 18, 2022, 11:22 AM

(Reuters) - Malaysian researchers found that treatment with the anti-parasite drug ivermectin did not prevent patients with COVID-19 from becoming severely ill in a randomized clinical trial published in the JAMA Internal Medicine journal on Friday.

The researchers said their findings do not support the use of ivermectin for patients with COVID-19.

The study enrolled 490 patients with mild to moderate illness at 20 hospitals and a COVID-19 quarantine center in Malaysia. Everyone received standard care; half the group also received ivermectin.

Severe disease developed in 21.6% of the patients given ivermectin and in 17.3% of those who received only standard care, the researchers said. They defined severe disease as requiring oxygen to help with breathing.

There were no statistically significant differences between the groups in rates of ICU admission, need for mechanical ventilation, or death, according to the study.

-snip-

Read more: https://news.yahoo.com/ivermectin-ineffective-preventing-severe-covid-162202670.html

______________________________________________________________________

Source: JAMA Internal Medicine

Original Investigation
February 18, 2022

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

The I-TECH Randomized Clinical Trial

JAMA Intern Med. Published online February 18, 2022. doi:10.1001/jamainternmed.2022.0189

Key Points

Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?

Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.

Meaning The study findings do not support the use of ivermectin for patients with COVID-19.

-snip-

Read more: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362